Contineum’s test drug may reverse multiple sclerosis damage
Contineum Therapeutics, Inc., a US San Diego-headquartered biopharmaceutical company’s trial drug may reverse multiple sclerosis damage by potentially restoring movement and function.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Contineum Therapeutics, Inc., a US San Diego-headquartered biopharmaceutical company’s trial drug may reverse multiple sclerosis damage by potentially restoring movement and function.
HQ Team July 5, 2023: Researchers found a genetic variant that increases the severity of multiple sclerosis (MS) and may pave the way.